NEW DELHI: Revised maximum retail prices of 1,364 anti-cancer medicine formulations came into effect across India on Monday, following a decision by the National Pharmaceutical Pricing Authority (NPPA) to rationalise trade margins on cancer drugs.
The Department of Pharmaceuticals said the price changes are expected to provide annual savings of approximately ₹3,540.38 crore to consumers. The initiative covers 137 anti-cancer drugs identified for trade margin rationalisation.
As of November 8, 85 pharmaceutical companies had reported revised prices for 1,364 formulations covering 121 drugs. The highest reported reduction in maximum retail price stands at 96.45 per cent, while 679 brands have reported price reductions exceeding 50 per cent.
The decision follows recommendations made by an expert committee constituted by the Directorate General of Health Services under the Ministry of Health and Family Welfare.
The NPPA has directed pharmaceutical companies to ensure that the revised prices are reflected in the market. Consumers have been advised to check the updated maximum retail price printed on medicine packaging before purchasing anti-cancer drugs.
The government said chemists and hospital pharmacies cannot charge more than the revised MRP. Patients who face overcharging can register complaints through the Pharma Jan Samadhan portal or contact the NPPA helpline.
The revised pricing initiative is aimed at reducing the financial burden on cancer patients and their families. Cancer treatment often involves prolonged medication, diagnostic procedures, hospital visits and follow-up care, making affordability an important concern.
The
Comment here